INNOGLY is the acronym of the CA18103: “INNOvation with GLYcans: new frontiers from synthesis to new biological targets”, a COST Action which has been recently approved (November 2018). To date, the CA18103 consists of a consortium of 26 COST Member Countries, including 12 Inclusiveness Target Countries (ITC) and Israel as Cooperating Member, and, in addition, one International Organization (USA). The main aim of INNOGLY is to build up a multidisciplinary group of researchers to move forward new concepts, ideas and approaches to address glycan-related scientific challenges from new and wider perspectives.
It consists of four Working Groups, which are focused on:
- WG1: Glycan-based correlations in developmental and cancer biology.
- WG2: Glycan dependent modulation of autophagy: cancer, lysosomal disorders and neurodegenerative diseases.
- WG3: Glycan dependent fine tuning of immunity.
- WG4: Exploring the multifaceted roles of glycosaminoglycans (GAGs)
The goal of the next four years is to forge and foster collaborations among researchers, within an intriguing “platform” capable of hosting a multidisciplinary team of scientists with diverse background in related but well distinct fields, such as biology, chemistry and physics, in order to achieve a wider, overall perspective. In addition, INNOGLY COST Action would be a great opportunity for young and smart researchers to get trained in the innovations of glycoscience and to find new career opportunities.
Now, take a look at our Memorandum of Understanding (https://www.cost.eu/actions/CA18103/#tabs|Name:overview) and join us in this exciting four years adventure!